CPPCC member to ling wu: modify unreasonable pricing policy on the patent traditional Chinese medicine
 
 
Qq finance 2014-03-04
 
 
 
The CPPCC national committee, the Chinese academy of engineering, ridge pharmaceutical chairman wu ridge proposal:
 
Suggest that changes as soon as possible on the patent Chinese medicine unreasonable pricing policy 

        21st century life science development is facing major changes from the reductionism to the integral regression, when reductionism mind facing the complexity of clinical diseases which cause serious damage to the human health is becoming more and more shows its limitations, contains the whole systematic thinking of Chinese traditional culture, traditional Chinese medicine is becoming more and more shows its original advantages. Academic theory innovation brings new strategy, the original formula, complexity of clinical disease treatment to improve curative effect, are increasingly being the attention of domestic medicine, Chinese medicine embodies the different from the original thinking of the overall advantages of chemical medicine in medical system reform and the clinical prevention and control of major diseases plays an increasingly important role. 
 
        Patent Chinese medicine and patent drugs have reflected the progress of medical technology, patent find the chemical structure of chemical medicine is based on the reduction methods, patent Chinese medicine is based on the theoretical formula of original, improve curative effect and obtained patent of new drugs. In recent years, many patent Chinese medicine through the large sample, randomized, double-blind, multicenter clinical evidence-based evaluation have the same clinical curative effect and chemical medicine and even its special advantage. Such as Zhang Boli hosted by academician patent Chinese medicine dropping pill ginseng and astragalus yiqi 2 levels of prevention of myocardial infarction and enteric aspirin. Hosted by fuwai cardiovascular hospital patent Chinese medicine tongxinluo capsule in treatment of acute myocardial infarction PCI postoperative clinical research flow, results show that the 24 h emergency PCI postoperative ecg curative effect of tongxinluo treatment group is 20% higher than pure western medicine group, significantly increased myocardial perfusion and microcirculation perfusion, significantly improve cardiac function, shows that patent Chinese medicine in the international medical community to solve problem, within 24 h emergency rescue cost tens of thousands of yuan of acute myocardial infarction (ami), ecg curative effect of tongxinluo treatment group increased by 20%, increase in cost of daily dozen yuan, its potency than advantage is obvious. Patent traditional Chinese medicine and shensong yangxin capsule in treatment of ventricular premature beat curative effect is superior to contrast, western medicine with western medicine treatment of paroxysmal atrial fibrillation, it is lack of effective drug treatment the curative effect is tardy arrhythmia. Patent traditional Chinese medicine (TCM) stilbene Li strong heart capsule for the treatment of chronic heart failure curative effect significantly better than pure western medicine group, the paper published in the journal of the American college of cardiology (JACC, impact factor: 14 points), the editorial said: "the most promising research has opened the how to use the latest technology to study traditional Chinese medicine in the treatment of heart failure in synergy, this is a challenge, we should have a warm hug", cause the extensive concern of the international medical community. Patent Chinese medicine even take antipyretic capsule treatment of swine flu in the flu symptoms relief time, turn the virus nucleic acid with tamiflu, antifebrile, alleviate the symptom such as cough, sore throat, fatigue is better than that of tamiflu without drug side effects, its price is only 1/8 of tamiflu, when domestic flu outbreak has played a positive role in the prevention and control, the current flows of the drug as a planning commission a/h1n1 flu, b, human bird flu diagnosis treatment guidelines recommend medication and expert consensus. The internationally accepted evidence-based medicine result shows that patent Chinese medicine major disease in cardio-cerebrovascular diseases and the a/h1n1 flu and other public health events with chemical medicine plays the same important role, become China's medical system reform and the special advantage of major disease prevention and cure. 
 
        But features advantages of traditional Chinese medicine has not yet been fully recognized, the role in the medical system reform has failed to get into full play, the relevant departments of the relativity of the original advantage of patent Chinese medicine and medicine curative effect characteristic understanding insufficiency, thus on the patent Chinese medicine practice is different from chemical innovative drug pricing policy, such as the current pricing method according to the state development planning commission released in November 2000 "notice about government pricing method of the drug, chemical class of drug pricing standards for sales margin rate 30%, 45%. While on the patent Chinese medicine reference to common drugs, pricing standards for sales margin rate 10%, 10%, is with patent drugs, only the diference between Chinese and western medicine, chemistry and Chinese traditional medicine formula, pricing two standardized drug costs by 75%, patent Chinese medicine is only 20%, this is clearly on the patent Chinese medicine pricing discrimination, so pricing enterprise will be how to deal with the patent Chinese medicine raw materials price rise quickly, the manufacturing cost increased pressure, more talk of scientific and technological innovation, obviously it will discourage innovative Chinese medicine enterprise development seriously, the serious influence the development of the national pharmaceutical industry. When the European developed countries to realize the limitations of single drug registration and open Chinese traditional medicine, some multinational pharmaceutical companies are actively buying Chinese medicine enterprises seize market commanding heights, the current patent Chinese medicine pricing policy clearly robbed national pharmaceutical enterprises of science and technology innovation and market competitiveness, the negative effects on the national pharmaceutical industry development in our country will be long-term and serious. The party central committee always adhere to the policy of paying equal attention to Chinese and western medicine, in traditional Chinese medicine and chemical medicine patent protection and pricing policy should be as equal, should not be one-sided discrimination patent Chinese medicine. 
 
        Advice: 
 
        Patent Chinese medicine and the kind of medicine to take the same pricing method, modified as soon as possible for the discriminatory pricing policy of Chinese traditional medicine, especially for after evidence-based medicine evaluation of curative effect is compared with the chemical medicine patent Chinese medicine should give more policy support.